Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dana V Rizk

Showing results (1-10 of 80) with videos related to

Pageof 8
Sort By:
Seminars in Nephrology|March 13, 2025
Updates on IgA NephropathyDana V Rizk
Kidney International|March 21, 2026
Predicting steroid treatment benefit in IgA nephropathy: are we ready for precision care?Dana V Rizk
Advances in Chronic Kidney Disease|June 28, 2014
The interdisciplinary team: the whole is larger than the partsNakshatra Saxena, Dana V Rizk
Kidney International|January 4, 2021
The mystery of cherry red ultrafiltrate in continuous renal replacement therapyNaveen Bade, Dana V Rizk
Kidney360|November 6, 2023
Evolution of Therapy for ANCA-Associated Vasculitis with Kidney InvolvementArun Rajasekaran, Dana V Rizk
Kidney360|July 18, 2022
The Forgotten Cost of Nephrotic Syndrome to Patients and Caregivers in the United StatesArun Rajasekaran, Dana V Rizk
Kidney International|July 2, 2011
Warfarin-related nephropathy: another newly recognized complication of an old drugDana V Rizk, David G Warnock
Kidney International|December 10, 2015
Migrated intra-jejunal peritoneal dialysis catheterVinay Narasimha Krishna, Dana V Rizk
Current Opinion in Nephrology and Hypertension|May 24, 2024
Antineutrophil cytoplasmic antibody-associated vasculitisRaghunandan Konda, Arun Rajasekaran, Dana V Rizk
The New England Journal of Medicine|May 14, 2025
Alternative Complement Pathway, Iptacopan, and IgA Nephropathy. ReplyJonathan Barratt, Vlado Perkovic, Dana V Rizk
Pageof 8

Showing results (1-10 of 80) with videos related to

Sort By:
Pageof 8
Seminars in Nephrology|March 13, 2025
Updates on IgA NephropathyDana V Rizk
Kidney International|March 21, 2026
Predicting steroid treatment benefit in IgA nephropathy: are we ready for precision care?Dana V Rizk
Advances in Chronic Kidney Disease|June 28, 2014
The interdisciplinary team: the whole is larger than the partsNakshatra Saxena, Dana V Rizk
Kidney International|January 4, 2021
The mystery of cherry red ultrafiltrate in continuous renal replacement therapyNaveen Bade, Dana V Rizk
Kidney360|November 6, 2023
Evolution of Therapy for ANCA-Associated Vasculitis with Kidney InvolvementArun Rajasekaran, Dana V Rizk
Kidney360|July 18, 2022
The Forgotten Cost of Nephrotic Syndrome to Patients and Caregivers in the United StatesArun Rajasekaran, Dana V Rizk
Kidney International|July 2, 2011
Warfarin-related nephropathy: another newly recognized complication of an old drugDana V Rizk, David G Warnock
Kidney International|December 10, 2015
Migrated intra-jejunal peritoneal dialysis catheterVinay Narasimha Krishna, Dana V Rizk
Current Opinion in Nephrology and Hypertension|May 24, 2024
Antineutrophil cytoplasmic antibody-associated vasculitisRaghunandan Konda, Arun Rajasekaran, Dana V Rizk
The New England Journal of Medicine|May 14, 2025
Alternative Complement Pathway, Iptacopan, and IgA Nephropathy. ReplyJonathan Barratt, Vlado Perkovic, Dana V Rizk
Pageof 8